Telo Genomics to present abstract at myeloma meeting

Mr. Guido Baechler reports INTERNATIONAL MYELOMA SOCIETY ACCEPTS TELO GENOMICS' MRD ABSTRACT FOR PRESENTATION AT ITS 2025 MEETING The International Myeloma Society has accepted Telo Genomics Corp.'s abstract submission for a poster presentation on minimal residual disease during the coming 22nd International Myeloma Society annual meeting in Toronto, Canada. The new abstract titled "3-D Telomere Profiling of MRD (Minimal Residual Disease) in Liquid Biopsy as a Predictive Marker of Disease Stability or Progression" will be presented at the meeting by Dr. Yulia Shifrin, laboratory director of Telo Genomics and published in Clinical Lymphoma, Myeloma & Leukemia. The abstract entails a technical methodology of MRD assessment based on TeloView profiling. Details of the abstract will be provided after the poster session. TeloView MM-MRD's proprietary approach of counting and profiling individual MRD cells has the potential to provide actionable information on risk of relapse to clinicians. The International Myeloma Society is a global professional organization dedicated to advancing the science and treatment of multiple myeloma. Its coming 22nd annual meeting will take place from Sept. 17 to Sept. 20, 2025. IMS meetings are widely considered as a defining annual forum in the myeloma field. "We are excited to share the next clinical application of our 3-D telomere application for MRD for multiple myeloma at IMS," said Dr. Sabine Mai, Telo's co-founder. "The acceptance is a result of our commitment to develop a clinical offering and a novel approach of liquid biopsy MRD." The company announces that, further to its news release dated Feb. 27, 2025, the company has issued an aggregate of 411,539 common shares to Trusted Health Advisors LLC to compensate THA for its provision of services related to the partnering and commercialization of Telo's diagnostic technologies from January to July 1, 2025. Pursuant to the agreement between THA and the company, 214,605 shares were issued at a deemed price of 12 cents per share, and 196,934 shares were issued at a deemed price of 12.5 cents per share, for total consideration of approximately $50,369, or $36,000 (U.S.). All shares are subject to a four-month hold period expiring Nov. 11, 2025, in accordance with applicable securities law and TSX Venture Exchange policies. In addition, the shares issued at 12 cents per share are subject to a voluntary resale restriction expiring March 31, 2026, and the shares issued at 12.5 cents per share are subject to a voluntary resale restriction expiring June 30, 2026. About MRD assessment Minimal residual disease is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells, between being in remission or active, that provide important actionable information for clinicians. Also, the Food and Drug Administration's oncologic drugs advisory committee voted unanimously in April, 2024, to accept MRD as a clinical end point for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals in multiple myeloma. MRD testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies and a growing emphasis on personalized health care, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is expected to reach $4.1-billion (U.S.) by 2032 (Globe Newswire -- Aug. 14, 2023). About multiple myeloma Multiple myeloma is a challenging and potentially deadly blood cancer that involves plasma cells, a type of blood cell that helps to fight infection. It is the second-most-common blood cancer with an incidence of 35,000 new cases every year in the United States and approximately 180,000 patients receiving treatment at any given time. The introduction of next-generation therapies (including targeted treatments) has increased the median survival rate to over five years, but MM is still considered incurable. Two asymptomatic precursors, monoclonal gammopathy of unknown significance and SMM generally precede the progression to classic symptomatic MM. While MGUS carries a steady risk of progression of 1 per cent per year, SMM is more heterogenous with nearly 40 per cent of patients progressing in the first five years, 15 per cent in the next five years, reaching the same low risk as MGUS after 10 years. To date, identifying patients who will more rapidly progress to MM remains an important clinical need. MM treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of two years, identifying them pro-actively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the U.S. About Telo Genomics Corp. Telo Genomics is a biotech company pioneering the most comprehensive telomere platform in the industry with powerful applications and prognostic solutions. These include liquid biopsies and related technologies in oncology and neurological diseases. Liquid biopsy is a rapidly growing field of significant interest to the medical community for being less invasive and more easily replicated than traditional diagnostic approaches. By combining its team's considerable expertise in quantitative analysis of 3-D telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, Telo Genomics is developing simple and accurate products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers. The benefits of the company's proprietary technology have been substantiated in 160-plus peer-reviewed publications and in 30-plus clinical studies involving more than 3,000 patients with multiple cancers and Alzheimer's disease. Its lead application, Telo-MM, is being developed to provide important, actionable information to medical professionals in the treatment of multiple myeloma, a deadly form of blood cancer. We seek Safe Harbor.